Jefferies Financial Group Inc. Sells 58,315 Shares of Amicus Therapeutics, Inc. $FOLD

Jefferies Financial Group Inc. lowered its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 26.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 165,485 shares of the biopharmaceutical company’s stock after selling 58,315 shares during the period. Jefferies Financial Group Inc. owned 0.05% of Amicus Therapeutics worth $1,304,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Allianz Asset Management GmbH boosted its holdings in Amicus Therapeutics by 0.3% in the 3rd quarter. Allianz Asset Management GmbH now owns 389,109 shares of the biopharmaceutical company’s stock valued at $3,066,000 after purchasing an additional 1,333 shares during the period. Parallel Advisors LLC increased its holdings in shares of Amicus Therapeutics by 40.2% in the third quarter. Parallel Advisors LLC now owns 5,756 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 1,649 shares during the period. CANADA LIFE ASSURANCE Co raised its position in shares of Amicus Therapeutics by 2.8% in the second quarter. CANADA LIFE ASSURANCE Co now owns 83,764 shares of the biopharmaceutical company’s stock worth $480,000 after buying an additional 2,263 shares in the last quarter. Arizona State Retirement System raised its position in shares of Amicus Therapeutics by 4.0% in the third quarter. Arizona State Retirement System now owns 72,846 shares of the biopharmaceutical company’s stock worth $574,000 after buying an additional 2,832 shares in the last quarter. Finally, Osaic Holdings Inc. boosted its stake in Amicus Therapeutics by 450.1% during the second quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 3,358 shares during the period.

Insider Transactions at Amicus Therapeutics

In related news, insider David Michael Clark sold 25,643 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $11.00, for a total value of $282,073.00. Following the completion of the sale, the insider owned 271,332 shares in the company, valued at $2,984,652. The trade was a 8.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Bradley L. Campbell sold 77,926 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $10.86, for a total value of $846,276.36. Following the completion of the sale, the chief executive officer owned 1,129,782 shares of the company’s stock, valued at $12,269,432.52. The trade was a 6.45% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 226,711 shares of company stock worth $2,887,822. 2.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

FOLD has been the subject of several recent analyst reports. Zacks Research cut Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 26th. Needham & Company LLC cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amicus Therapeutics in a research report on Monday, December 29th. Citigroup reissued a “neutral” rating and set a $14.50 price objective (down from $17.00) on shares of Amicus Therapeutics in a report on Monday, December 22nd. Finally, Cantor Fitzgerald cut shares of Amicus Therapeutics from an “overweight” rating to a “hold” rating and decreased their price objective for the stock from $21.00 to $14.50 in a research report on Friday, December 19th. Three analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Amicus Therapeutics has an average rating of “Hold” and an average target price of $15.39.

Amicus Therapeutics Stock Up 0.1%

Shares of NASDAQ:FOLD opened at $14.37 on Thursday. The firm has a market capitalization of $4.51 billion, a PE ratio of -179.63 and a beta of 0.43. The company has a debt-to-equity ratio of 1.43, a quick ratio of 1.88 and a current ratio of 2.84. Amicus Therapeutics, Inc. has a 52-week low of $5.51 and a 52-week high of $14.39. The firm has a fifty day moving average of $14.31 and a 200 day moving average of $11.07.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Friday, February 20th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.03). Amicus Therapeutics had a negative net margin of 4.27% and a positive return on equity of 4.15%. The firm had revenue of $185.21 million for the quarter, compared to analysts’ expectations of $185.00 million. During the same quarter in the previous year, the business earned $0.09 EPS. The company’s revenue for the quarter was up 23.7% on a year-over-year basis. As a group, research analysts anticipate that Amicus Therapeutics, Inc. will post 0.15 EPS for the current fiscal year.

About Amicus Therapeutics

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.